Disease · MONDO_0009348
Comparisons in its trials33
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
1 to 20 of 33
Download this page as JSON| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| A+AVD vs ABVD: Number of Participants With Abnormal Clinical Laboratory Values | 662 of 662 | 658 of 659 | 1,321 | NCT01712490 | Trial comparisons |
| A+AVD vs ABVD: deaths from any cause | 9 of 662 | 13 of 659 | 1,321 | NCT01712490 | Trial comparisons |
| A+AVD vs ABVD: serious adverse events | 284 of 662 | 178 of 659 | 1,321 | NCT01712490 | Trial comparisons |
| Arm I (Chemotherapy, Nivolumab, Radiation) vs Arm II (Chemotherapy, Brentuximab Vedotin, Radiation): Overall Survival | 7 of 487 | 14 of 483 | 970 | NCT03907488 | Trial comparisons |
| Arm I (Chemotherapy, Nivolumab, Radiation) vs Arm II (Chemotherapy, Brentuximab Vedotin, Radiation): Event-free Survival (EFS) | 52 of 487 | 91 of 483 | 970 | NCT03907488 | Trial comparisons |
| Arm I (Chemotherapy, Nivolumab, Radiation) vs Arm II (Chemotherapy, Brentuximab Vedotin, Radiation): Progression Free Survival (PFS) | 41 of 487 | 81 of 483 | 970 | NCT03907488 | Trial comparisons |
| Arm I (Chemotherapy, Nivolumab, Radiation) vs Arm II (Chemotherapy, Brentuximab Vedotin, Radiation): deaths from any cause | 7 of 487 | 14 of 483 | 970 | NCT03907488 | Trial comparisons |
| Arm I (Chemotherapy, Nivolumab, Radiation) vs Arm II (Chemotherapy, Brentuximab Vedotin, Radiation): serious adverse events | 140 of 481 | 18 of 476 | 957 | NCT03907488 | Trial comparisons |
| Arm I (ABVE-PC) vs ARM II (Bv-AVEPC): deaths from any cause | 4 of 289 | 2 of 298 | 587 | NCT02166463 | Trial comparisons |
| Arm I (ABVE-PC) vs ARM II (Bv-AVEPC): serious adverse events | 11 of 287 | 66 of 295 | 582 | NCT02166463 | Trial comparisons |
Cohort 1: Relapsed/Refractory Classic Hodgkin Lymphoma - Low Risk Relapse vs Cohort 2: Relapsed/Refractory Classic Hodgkin Lymphoma - Standard Risk Relapse: The Number of Participants With Serious Adverse Events (SAEs) | 8 of 28 | 9 of 44 | 72 | NCT02927769 | Trial comparisons |
Cohort 1: Relapsed/Refractory Classic Hodgkin Lymphoma - Low Risk Relapse vs Cohort 2: Relapsed/Refractory Classic Hodgkin Lymphoma - Standard Risk Relapse: The Number of Participants With Adverse Events (AEs) | 26 of 28 | 42 of 44 | 72 | NCT02927769 | Trial comparisons |
| Relapsed or Refractory Classical Hodgkin's Lymphoma (rrcHL) vs Relapsed or Refractory Primary Mediastinal Large B-cell Lymphoma (rrPMBCL): deaths from any cause | 9 of 60 | 3 of 6 | 66 | NCT04875195 | Trial comparisons |
| Relapsed or Refractory Classical Hodgkin's Lymphoma (rrcHL) vs Relapsed or Refractory Primary Mediastinal Large B-cell Lymphoma (rrPMBCL): serious adverse events | 5 of 60 | 0 of 6 | 66 | NCT04875195 | Trial comparisons |
| RABVD vs ABVD: deaths from any cause | 5 of 26 | 6 of 32 | 58 | NCT00654732 | Trial comparisons |
| RABVD vs ABVD: serious adverse events | 13 of 26 | 13 of 32 | 58 | NCT00654732 | Trial comparisons |
| RABVD vs ABVD: Event-free Survival (EFS) Rate | 17 of 22 | 20 of 26 | 48 | NCT00654732 | Trial comparisons |
| Cohort 1 vs Cohort 2: deaths from any cause | 3 of 14 | 9 of 31 | 45 | NCT04318080 | Trial comparisons |
| Cohort 1 vs Cohort 2: serious adverse events | 4 of 14 | 9 of 31 | 45 | NCT04318080 | Trial comparisons |
| Brentuximab Vedotin 1.8 mg/kg (HL) vs Brentuximab Vedotin 1.8 mg/kg (sALCL): Number of Participants With Treatment-Emergent Adverse Events (TEAEs) | 30 of 30 | 9 of 9 | 39 | NCT02939014 | Trial comparisons |
diseases-2026-09-18-0.1.0
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0009348/comparisons